CTLA4 and breast cancer: In order to gauge how BC patients in the two separate risk categories responded to anti-PD-1/PD-L1 and anti-CTLA-4 medication, two subtypes of IPS values—IPS-PD-1/PD-L1 pos and IPS-CTLA-4 pos—were utilized [19].